Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry

SIMPLE SUMMARY: Nivolumab combined with ipilimumab has improved the prognosis of patients with advanced melanoma. However, this therapy is frequently associated with immune-related adverse events. Published data suggested that objective responses rates appear to be superior in patients who developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Serna-Higuita, Lina María, Amaral, Teresa, Forschner, Andrea, Leiter, Ulrike, Flatz, Lukas, Seeber, Olivia, Thomas, Ioannis, Garbe, Claus, Eigentler, Thomas Kurt, Martus, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657404/
https://www.ncbi.nlm.nih.gov/pubmed/34885249
http://dx.doi.org/10.3390/cancers13236141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657404/
https://www.ncbi.nlm.nih.gov/pubmed/34885249
http://dx.doi.org/10.3390/cancers13236141

Ejemplares similares